<DOC>
	<DOCNO>NCT01254630</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study ass safety tolerability V212 administer adult solid tumor malignancy ( STM ) hematologic malignancy ( HM ) determine whether V212 reduces incidence herpes zoster ( HZ ) adult STM HM , compare placebo .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Inactivated Varicella-zoster Vaccine ( VZV ) Preventative Treatment Herpes Zoster ( HZ ) HZ-related Complications Adult Participants With Solid Tumor Hematologic Malignancy ( V212-011 )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion ; Participant diagnose STM HM likely undergo hematopoietic cell transplant ( HCT ) : Participant ≥18 year age receive cytotoxic immunosuppressive chemotherapy regimen Participant ≥ 50 year age hematologic malignancy remission , whether therapy Participant life expectancy ≥ 12 month . Participant prior history varicella antibody VZV due exposure disease country disease common . Exclusion criterion : Participant history allergic reaction vaccine component ( include gelatin ) anaphylactic/anaphylactoid reaction neomycin . Participant prior history HZ within 1 year enrollment . Participant receive expected receive varicella nonstudy zoster vaccine . Participant currently receive expect receive longterm antiviral prophylaxis ( &gt; 4 week duration ) activity herpes simplex virus ( HSV ) , VZV cytomegalovirus ( CMV ) Participant pregnant breastfeeding expect conceive within period 2 week prior enrollment throughout 6 month last vaccination dose . Participant live virus vaccine administer scheduled period 4 week prior Dose 1 28 day post vaccination dose 4 Participant inactivate vaccine administer schedule within period 7 day prior , 7 day follow , dose study vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Herpes zoster</keyword>
	<keyword>vaccine</keyword>
	<keyword>solid tumor malignancy</keyword>
	<keyword>hematologic malignancy</keyword>
	<keyword>immunocompromised</keyword>
	<keyword>herpes-zoster-related complication</keyword>
</DOC>